Key takeaways:
The Science: Editing One Gene to Lower Cholesterol
The therapy, called VERVE-102, targets a gene called PCSK9.
PCSK9 is a protein that reduces your liver’s ability to clear LDL cholesterol from your blood. The more PCSK9 activity you have, the fewer LDL "receptors" your liver keeps available to pull LDL particles out of circulation. Some people are born with naturally low-functioning PCSK9 genes, and they tend to have markedly lower LDL across their entire lives and substantially lower rates of heart disease, with no apparent downside. In other words, turning down PCSK9 is a known protective pattern scientists have studied for two decades. We already have approved PCSK9-lowering drugs, but they require ongoing injections.
What’s new is the delivery. VERVE-102 uses base editing, a precise form of gene editing, to make a single change to the PCSK9 gene in liver cells after one infusion. The goal is to do once, durably, what current drugs do repeatedly.
In the Heart-2 trial, the early results were striking. A single dose lowered LDL cholesterol by an average of around 50%, and by as much as roughly 69% at the higher doses, with reductions holding for up to 18 months. The therapy was well tolerated, with no treatment-related serious adverse events reported.
The Bottom Line: A one-time gene editing infusion produced large, durable reductions in LDL cholesterol in an early trial, by mimicking a protective genetic pattern that already exists in nature.
The honest caveats:
The headline is easy to over-read, so here’s the careful version.
It’s a phase 1b trial. That’s an early stage focused mainly on safety and initial signals, in a small number of participants. It has not yet been shown to prevent heart attacks, strokes, or cognitive decline.
It’s a specific patient group. The trial enrolled people with an inherited form of very high cholesterol or early coronary artery disease, who need aggressive LDL lowering. These are not general-population results.
Gene editing is genuinely new. The PCSK9 mechanism is exceptionally well understood, which is reassuring. But making a permanent edit to a gene is a young field, and the long-term safety story takes years to write. As a result, this drug is likely to be approved initially for very high-risk individuals such as those with familial hypercholesterolemia. It could be prescribed off-label, but it is likely to be very expensive.
It’s years away. The next step is a larger phase 2 trial. Broad availability is well down the road.
Why this is a brain-health story, not just a heart story
At BetterBrain, we look at the whole body, because your brain doesn’t exist in isolation from it. And few things connect the two as directly as lipids.
Start with ApoB. You’ve probably heard of LDL cholesterol. ApoB is the more precise number underneath it. Every LDL particle carries exactly one ApoB protein, so LDL-C tells you the amount of cholesterol in LDL particles, while ApoB tells you the number of particles actually driving damage in your artery walls. When the two disagree, ApoB is the better predictor of risk. Lowering PCSK9, whether through these new therapies or the drugs we already have, lowers both.
Now connect it to the brain. The blood vessels that feed your brain are subject to the same lipid-driven damage as the ones feeding your heart, and that vascular damage is one of the major pathways of cognitive decline. Protecting your lipids over a lifetime is protecting your brain. This is especially true for people who tend to run higher LDL, including APOE4 carriers, which is one reason lipid management is a core part of what we do at BetterBrain.
And here’s the bigger picture.Between therapies like this one and the medications we already have, the tools for managing cardiovascular disease are getting remarkably good, and they’re only going to get better. But adding years to your life is only valuable if your brain is still working well for those years. That’s the conversation most people aren’t having yet, and it’s the one that matters most to us at BetterBrain.
What this means for you, right now
You don’t have to wait for a therapy that’s years away. The target itself, your lipid health, is something you can measure and move today.
Get your ApoB tested, not just standard cholesterol. ApoB counts the particles actually driving damage, and it’s one of the most informative markers for both heart and brain health.
Think of lipids as a lifelong number. The PCSK9 story shows that it’s the decades of cumulative exposure that drive risk, which means small, steady improvements compound in your favor. Starting earlier is always worth more than starting perfectly.
Use the levers you already have. Diet, regular movement, and, where your physician recommends them, proven medications all lower lipids today.
Your BetterBrain coach can pull your ApoB and your full lipid picture into one clear plan, so that whatever arrives in five or ten years, you’ve protected the decades in between.
.webp)